Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 1/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.79 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboprine SCHEMBL1763190 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL16805426 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL29552839 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL4815729 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL4599 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL18870819 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| Riboprine SCHEMBL4600 | 1.00 | TP53 (0.79) | TP53LMNAALOX15TSHRHTT | |
| SCHEMBL25170535 | 0.99 | TP53 (0.78) | TP53LMNAALOX15TSHRHTT | |
| SCHEMBL31307032 | 0.99 | TP53 (0.78) | TP53LMNAALOX15TSHRHTT | |
| SCHEMBL8706995 | 0.99 | TP53 (0.78) | TP53LMNAALOX15TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170044619-A1 | PROFILING CHEMICALLY MODIFIED DNA/RNA UNITS FOR DISEASE AND CANCER DIAGNOSIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | TP53 411/4885LMNA 571/4885ALOX15 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.